Skip to main content
Erschienen in: Clinical and Experimental Nephrology 4/2019

20.10.2018 | Original article

Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells

verfasst von: Tomomi Aizawa, Tadaatsu Imaizumi, Koji Hirono, Shojiro Watanabe, Koji Tsugawa, Hiroshi Tanaka

Erschienen in: Clinical and Experimental Nephrology | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Chloroquine, an antimalarial agent, has been reported to prevent the risk of thrombosis and decrease renal damage in patients with systemic lupus erythematosus (SLE); however, its detailed mechanisms remain unclear. Plasminogen activator inhibitor-1 (PAI-1) is an inhibitor of fibrinolysis and is involved in fibrin deposition in glomeruli. Since upregulation of glomerular Toll-like receptor 3 (TLR3) signaling reportedly plays a pivotal role in the pathogenesis of lupus nephritis (LN), we examined whether chloroquine affects TLR3-mediated expression of PAI-1 in cultured human glomerular endothelial cells (GECs).

Methods

We examined the effect of polyinosinic-polycytidylic acid (poly IC), an authentic double-stranded RNA, on PAI-1 and tissue plasminogen activator (t-PA) expression in GECs. Then, we analyzed whether pretreatment of chloroquine or dexamethasone inhibits poly IC-induced expression of these proteins using reverse-transcriptase polymerase chain reaction and enzyme-linked immunosorbent assay.

Results

Poly IC increased PAI-1 expression in a time- and concentration-dependent manner, but did not affect t-PA expression in GECs. RNA interference against TLR3 inhibited poly IC-induced PAI-1 expression. Interestingly, pretreating cells with chloroquine, and also hydroxychloroquine, but not dexamethasone, attenuated poly IC-induced PAI-1 expression in GECs.

Conclusion

Considering that TLR3 signaling is implicated in LN pathogenesis, our results suggest that chloroquine exert postulated renoprotective effects by inhibiting PAI-1 expression.
Literatur
1.
Zurück zum Zitat Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–33.CrossRefPubMed Wallace DJ, Gudsoorkar VS, Weisman MH, Venuturupalli SR. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol. 2012;8:522–33.CrossRefPubMed
2.
Zurück zum Zitat Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42:968–78.CrossRefPubMed Tang C, Godfrey T, Stawell R, Nikpour M. Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. Intern Med J. 2012;42:968–78.CrossRefPubMed
3.
Zurück zum Zitat Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain JG, Aguirre C. Effect of antimalarials on thrombosis and survival in patient with systemic lupus erythematosus. Lupus. 2006;15:577–83.CrossRefPubMed Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain JG, Aguirre C. Effect of antimalarials on thrombosis and survival in patient with systemic lupus erythematosus. Lupus. 2006;15:577–83.CrossRefPubMed
4.
Zurück zum Zitat Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patient with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29–36.CrossRefPubMed Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patient with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29–36.CrossRefPubMed
5.
Zurück zum Zitat Bertsias G, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adults and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.CrossRefPubMedPubMedCentral Bertsias G, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adults and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Hamano K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, Dohi K. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis. 2002;39:695–705.CrossRefPubMed Hamano K, Iwano M, Akai Y, Sato H, Kubo A, Nishitani Y, Uyama H, Yoshida Y, Miyazaki M, Shiiki H, Kohno S, Dohi K. Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis. Am J Kidney Dis. 2002;39:695–705.CrossRefPubMed
7.
Zurück zum Zitat Hagberg N, Rönnblom L. Systemic lupus erythematosus—a disease with a dysregulated type I interferon system. Scand J Immunol. 2015;82:199–207.CrossRefPubMed Hagberg N, Rönnblom L. Systemic lupus erythematosus—a disease with a dysregulated type I interferon system. Scand J Immunol. 2015;82:199–207.CrossRefPubMed
8.
Zurück zum Zitat Anders HJ. Pseudoviral immunity—a novel concept for lupus. Trends Mol Med. 2009;15:553–61.CrossRefPubMed Anders HJ. Pseudoviral immunity—a novel concept for lupus. Trends Mol Med. 2009;15:553–61.CrossRefPubMed
9.
Zurück zum Zitat Hägele H, Allam R, Pawar RD, Anders HJ. Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-I. Nephrol Dial Transplant. 2009; 24: 3312–8.CrossRefPubMed Hägele H, Allam R, Pawar RD, Anders HJ. Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-I. Nephrol Dial Transplant. 2009; 24: 3312–8.CrossRefPubMed
10.
Zurück zum Zitat Wörnle M, Roeder M, Sauter M, Merkle M, Ribeiro A. Effect of dsRNA on mesangial cell synthesis of plasminogen activator inhibitor type 1 and tissue plasminogen activator. Nephron Exp Nephrol. 2009;113:e57–65.CrossRefPubMed Wörnle M, Roeder M, Sauter M, Merkle M, Ribeiro A. Effect of dsRNA on mesangial cell synthesis of plasminogen activator inhibitor type 1 and tissue plasminogen activator. Nephron Exp Nephrol. 2009;113:e57–65.CrossRefPubMed
12.
Zurück zum Zitat Imaizumi T, Aizawa T, Hayakari R, Xing F, Meng P, Tsuruga K, Matsumiya T, Yoshida H, Wang L, Tatsuta T, Tanaka H. Tumor necrosis factor-α synergistically enhances polyinosinic–polycytidylic acid-induced Toll-like receptor 3 signaling in cultured normal human mesangial cells: possible involvement in the pathogenesis of lupus nephritis. Clin Exp Nephrol. 2015;19:75–81.CrossRefPubMed Imaizumi T, Aizawa T, Hayakari R, Xing F, Meng P, Tsuruga K, Matsumiya T, Yoshida H, Wang L, Tatsuta T, Tanaka H. Tumor necrosis factor-α synergistically enhances polyinosinic–polycytidylic acid-induced Toll-like receptor 3 signaling in cultured normal human mesangial cells: possible involvement in the pathogenesis of lupus nephritis. Clin Exp Nephrol. 2015;19:75–81.CrossRefPubMed
13.
Zurück zum Zitat Imaizumi T, Hayakari R, Matsumiya T, Yoshida H, Tsuruga K, Watanabe S, Kawaguchi S, Tanaka H. Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: a possible protective effect against renal damage in lupus nephritis. Mod Rheumatol. 2017;27:1004–9.CrossRefPubMed Imaizumi T, Hayakari R, Matsumiya T, Yoshida H, Tsuruga K, Watanabe S, Kawaguchi S, Tanaka H. Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: a possible protective effect against renal damage in lupus nephritis. Mod Rheumatol. 2017;27:1004–9.CrossRefPubMed
14.
Zurück zum Zitat Liu Q, Imaizumi T, Kawaguchi S, Aizawa T, Matsumiya T, Watanabe S, Tsugawa K, Yoshida H, Tsuruga K, Joh K, Kijima H, Tanaka H. Toll-like receptor 3 signaling contributes to regional neutrophil recruitment in cultured human glomerular endothelial cells. Nephron. 2018;139:349–58.CrossRefPubMed Liu Q, Imaizumi T, Kawaguchi S, Aizawa T, Matsumiya T, Watanabe S, Tsugawa K, Yoshida H, Tsuruga K, Joh K, Kijima H, Tanaka H. Toll-like receptor 3 signaling contributes to regional neutrophil recruitment in cultured human glomerular endothelial cells. Nephron. 2018;139:349–58.CrossRefPubMed
15.
Zurück zum Zitat Bhargavan B, Kanmogne GD. Toll-like receptor-3 mediates HIV-1-induced interleukin-6 expression in the human brain endothelium via TAK1 and JNK pathways: implication for viral neuropathogenesis. Mol Neurobiol. 2018;55:5976–92.CrossRefPubMed Bhargavan B, Kanmogne GD. Toll-like receptor-3 mediates HIV-1-induced interleukin-6 expression in the human brain endothelium via TAK1 and JNK pathways: implication for viral neuropathogenesis. Mol Neurobiol. 2018;55:5976–92.CrossRefPubMed
16.
Zurück zum Zitat Keeton M, Ahn C, Eguchi Y, Burlingame R, Loskutoff DJ. Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int. 1995;47:148–57.CrossRefPubMed Keeton M, Ahn C, Eguchi Y, Burlingame R, Loskutoff DJ. Expression of type 1 plasminogen activator inhibitor in renal tissue in murine lupus nephritis. Kidney Int. 1995;47:148–57.CrossRefPubMed
17.
Zurück zum Zitat Imaizumi T, Hayakari R, Watanabe S, Aizawa T, Matsumiya T, Yoshida H, Tsuruga K, Kawaguch S, Tanaka H. Cylindromatosis (CYLD), a deubiquitinase, attenuates inflammatory signaling pathways by activating Toll-like receptor 3 in human mesangial cells. Kidney Blood Press Res. 2017;42:942–50.CrossRefPubMed Imaizumi T, Hayakari R, Watanabe S, Aizawa T, Matsumiya T, Yoshida H, Tsuruga K, Kawaguch S, Tanaka H. Cylindromatosis (CYLD), a deubiquitinase, attenuates inflammatory signaling pathways by activating Toll-like receptor 3 in human mesangial cells. Kidney Blood Press Res. 2017;42:942–50.CrossRefPubMed
Metadaten
Titel
Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells
verfasst von
Tomomi Aizawa
Tadaatsu Imaizumi
Koji Hirono
Shojiro Watanabe
Koji Tsugawa
Hiroshi Tanaka
Publikationsdatum
20.10.2018
Verlag
Springer Singapore
Erschienen in
Clinical and Experimental Nephrology / Ausgabe 4/2019
Print ISSN: 1342-1751
Elektronische ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1659-y

Weitere Artikel der Ausgabe 4/2019

Clinical and Experimental Nephrology 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.